Patent 9504762 was granted and assigned to Biomarin Pharmaceutical on November, 2016 by the United States Patent and Trademark Office.
The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.